Literature DB >> 22293945

Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach.

Tina Zahel1, Sabine Krysa, Esther Herpel, Albrecht Stenzinger, Benjamin Goeppert, Peter Schirmacher, Hans Hoffmann, Philipp A Schnabel, Arne Warth.   

Abstract

Pulmonary carcinoids (PC) are separated into typical (TC) and atypical carcinoids (ATC). However, the biological behavior cannot be reliably predicted, and in small biopsies differential diagnosis can be challenging. To provide a basis for a grading approach, we analyzed mitoses and the proliferative index (PI; Ki-67) of 200 PC specimens (TC: n = 114; ATC: n = 86). To define suitable diagnostic and to screen for putative therapeutic markers, CD56, CD57, CD99, CD117, TTF-1, synaptophysin, chromogranin A, CK 18, KL-1, epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (Her-2/neu), somatostatin receptor subtype 2A (SSTR2A), thymidylate synthase (TS), and excision repair cross-complementation group 1 (ERCC-1) expression was analyzed. A combination of synaptophysin and cytokeratins is the most sensitive marker panel for PC with unclear histomorphology. Predictive phenotyping revealed that SSTR2A is expressed in >80% of all PC and may be used both, as a diagnostic marker for imaging approaches and as a predictive marker for octreotide-based therapies. We introduced a grading system distinguishing between PC with low and highly aggressive biological behavior similar to the grading system for gastrointestinal neuroendocrine tumors. The system is superior to the classical separation into TC and ATC. This study indicates that PI in addition to mitotic count may improve prediction of the biological behavior of PC and should be validated in prospective studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22293945     DOI: 10.1007/s00428-012-1194-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  36 in total

1.  Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.

Authors:  David S Klimstra; Irvin R Modlin; N Volkan Adsay; Runjan Chetty; Vikram Deshpande; Mithat Gönen; Robert T Jensen; Mark Kidd; Matthew H Kulke; Ricardo V Lloyd; Cesar Moran; Steven F Moss; Kjell Oberg; Dermot O'Toole; Guido Rindi; Marie E Robert; Saul Suster; Laura H Tang; Chin-Yuan Tzen; Mary Kay Washington; Betram Wiedenmann; James Yao
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

2.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 3.  Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature.

Authors:  G Fink; T Krelbaum; A Yellin; D Bendayan; M Saute; M Glazer; M R Kramer
Journal:  Chest       Date:  2001-06       Impact factor: 9.410

4.  Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas.

Authors:  M H Lyda; L M Weiss
Journal:  Hum Pathol       Date:  2000-08       Impact factor: 3.466

5.  Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.

Authors:  W D Travis; W Rush; D B Flieder; R Falk; M V Fleming; A A Gal; M N Koss
Journal:  Am J Surg Pathol       Date:  1998-08       Impact factor: 6.394

6.  Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors.

Authors:  A L Folpe; A M Gown; L W Lamps; R Garcia; D H Dail; R J Zarbo; R A Schmidt
Journal:  Mod Pathol       Date:  1999-01       Impact factor: 7.842

7.  Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.

Authors:  K Oberg; I Norheim; E Theodorsson
Journal:  Acta Oncol       Date:  1991       Impact factor: 4.089

8.  ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.

Authors:  Birgit Guldhammer Skov; Bente Holm; Anders Erreboe; Torsten Skov; Anders Mellemgaard
Journal:  J Thorac Oncol       Date:  2010-04       Impact factor: 15.609

9.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

10.  Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.

Authors:  O Nilsson; L Kölby; B Wängberg; A Wigander; H Billig; L William-Olsson; M Fjälling; E Forssell-Aronsson; H Ahlman
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

View more
  27 in total

Review 1.  [Neuroendocrine tumors of the lungs. From small cell lung carcinoma to diffuse idiopathic pulmonary neuroendocrine cell hyperplasia].

Authors:  P A Schnabel; K Junker
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement.

Authors:  Na Liu; Jingjing Wang; Xiao Fu; Xiaoqiang Zheng; Huan Gao; Tao Tian; Zhiping Ruan; Yu Yao
Journal:  Cancer Biol Ther       Date:  2019-09-27       Impact factor: 4.742

3.  Ki-67 expression in pulmonary tumors-reply.

Authors:  Mark Kriegsmann; Arne Warth
Journal:  Transl Lung Cancer Res       Date:  2016-10

4.  [Current issues in pulmonary pathology. Report of the working group on pulmonary pathology of the German Society of Pathology].

Authors:  Ph A Schnabel; I Petersen; K Junker
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

5.  Ki-67 expression in pulmonary tumors.

Authors:  Lucian R Chirieac
Journal:  Transl Lung Cancer Res       Date:  2016-10

6.  Tumor cell proliferation, proliferative index and mitotic count in lung cancer.

Authors:  Lucian R Chirieac
Journal:  Transl Lung Cancer Res       Date:  2016-10

Review 7.  [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].

Authors:  A Warth
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

8.  Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors.

Authors:  Annika Blank; Laura Wehweck; Ilaria Marinoni; Laura Amanda Boos; Frank Bergmann; Anja Maria Schmitt; Aurel Perren
Journal:  Virchows Arch       Date:  2015-09-17       Impact factor: 4.064

Review 9.  Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.

Authors:  Giuseppe Pelosi; Mauro Papotti; Guido Rindi; Aldo Scarpa
Journal:  Endocr Pathol       Date:  2014-06       Impact factor: 3.943

10.  Survival and Predictors of Death for Patients with Bronchopulmonary Carcinoid at a Danish Tertiary NET Centre.

Authors:  Linda Skibsted Kornerup; Gitte Dam; Henning Gronbaek
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.